Pablo Cardenal-Morales

Mr. Pablo Cardenal-Morales

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 July 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
MEMaría Ezquerra-Durán
María Ezquerra-Durán
MFMaría Esther Durán Florez
María Esther Durán Florez
Luis Javier Ezquerra CalvoLuis Javier Ezquerra Calvo
Luis Javier Ezquerra Calvo
PCPablo Cardenal-Morales
Pablo Cardenal-Morales
MSMassimo Santella
Massimo Santella
Primary tracheal neoplasia is uncommon in domestic animals and humans, and most reported tracheal tumors are malignant. To the authors’ knowledge, this case represents the third confirmed tracheal leiomyoma reported in dogs. Similarly, in human medicine, tracheal leiomyomas have only been reported sporadically and account for approximately 1% of tracheal tumors. A 12-year-old spayed female Pitbull was presented as an emergency because of worsening recurrent respiratory signs that were refractory to medical treatment. On initial evaluation, reduced mobility of both arytenoid cartilages was observed, and left arytenoid lateralization was therefore performed. However, the patient continued to experience severe episodes of respiratory distress requiring orotracheal intubation. Subsequent bronchoscopy revealed an intraluminal tracheal mass partially obstructing the airway lumen. Because of this obstruction, an emergency temporary tracheostomy was performed caudal to the mass. Once the patient was clinically stabilized, computed tomography was performed to complete surgical planning. Surgical treatment consisted of segmental tracheal resection and end-to-end anastomosis, with removal of 24% of the total tracheal length. Histopathological examination confirmed the diagnosis of tracheal leiomyoma. Complete surgical excision was achieved, supporting a favorable prognosis.

28 January 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
PCPablo Cardenal-Morales
Pablo Cardenal-Morales
JCJosé Ignacio Cristóbal
José Ignacio Cristóbal
RCRafael Barrera Chacón
Rafael Barrera Chacón
AEAlberto Ezquerra-Durán
Alberto Ezquerra-Durán
PNPaloma Nicolas
Paloma Nicolas
Javier DuqueJavier Duque
Javier Duque
Myxomatous mitral valve disease (MMVD) is the most common acquired heart valve disease in dogs and it may contribute to cardiovascular-renal axis disorders (CvRD) in dogs. Sensitive and early biomarkers of renal involvement are needed. In this prospective and observational study, 84 dogs were enrolled (20 healthy dogs and 64 dogs with MMVD, categorized using the American College of Veterinary Internal Medicine guidelines. Serum and urinary parameters were analyzed, including tubular biomarkers expressed as creatinine-ratios: urinary alkaline phosphatase (uALPc), gamma-glutamyl transferase (uGGTc), N-acetyl-β-D-glucosaminidase (uNAGc) and cystatin C (uCystc). uALPc, uGGTc and uNAGc were higher in MMVD than in controls; uALPc and uGGTc were increased from stage B1, uNAGc was higher in stages with cardiomegaly (B2 and C+D), and uCystc increased mainly in clinical stages (C+D). Serum renal markers increased only in clinical stages. ROC analysis showed good discrimination for MMVD with uALPc (AUC 0.87) and uGGTc (0.86); for cardiomegaly with uALPc (0.77) and uNAGc (0.75); and for congestive heart failure with SDMA (0.85) and uCystc (0.75). No urinary biomarker was associated with daily furosemide dose. Urinary tubular biomarkers, particularly uALPc and uGGTc, detect early CvRD in dogs with MMVD and complement traditional serum markers.

24 July 2026 in Veterinary Sciences
Verified
Journal Article
Open access
PDF file
PNPaloma Nicolás-Barceló
Paloma Nicolás-Barceló
JFJesús Fortes-Díaz
Jesús Fortes-Díaz
RCRafael Barrera Chacón
Rafael Barrera Chacón
PCPablo Cardenal-Morales
Pablo Cardenal-Morales
JCJosé Ignacio Cristóbal
José Ignacio Cristóbal
Javier DuqueJavier Duque
Javier Duque
Doxorubicin-induced cardiotoxicity is an important concern in veterinary oncology, and early detection of myocardial injury remains clinically challenging. This exploratory pilot study described changes in cardiac fatty acid-binding protein (h-FABP), cardiac troponin I (cTnI), NT-proBNP, conventional echocardiographic variables, and 24-h Holter-derived heart rate variability parameters in dogs with hemangiosarcoma treated with doxorubicin. Fourteen dogs were prospectively evaluated before treatment initiation and one week after the third doxorubicin dose, corresponding to a cumulative dose of 90 mg/m2. The study did not include a control group, a predefined cardiotoxicity endpoint, or diagnostic-performance analysis. Plasma biomarkers, echocardiographic parameters, ventricular arrhythmic events, and Holter-derived time- and frequency-domain heart rate variability variables were compared between both time points. Cardiac troponin I increased significantly after three doxorubicin doses, from a median of 0.05 ng/mL to 0.15 ng/mL (p = 0.002). In contrast, h-FABP did not change significantly, with median values of 2.43 ng/mL at baseline and 2.62 ng/mL after treatment (p = 0.27). NT-proBNP also showed no significant change (p = 0.87). Among echocardiographic variables, E-point septal separation, fractional shortening, ejection fraction, LA/Ao, and LVDd index did not change significantly. Ventricular arrhythmic events were infrequent and were described descriptively, whereas Holter-derived HRV variables did not show statistically significant differences between time points. In this exploratory cohort, cTnI increased after three doxorubicin doses, whereas h-FABP and NT-proBNP did not change significantly at the evaluated time point. Because h-FABP was measured one week after treatment, its potential short-term post-infusion release cannot be assessed. Larger studies with serial early sampling, predefined cardiotoxicity endpoints, appropriate control groups, and adjusted statistical analyses are required.

7 September 2026 in Animals
Verified
Journal Article
Open access
PDF file
MEMaría Ezquerra-Durán
María Ezquerra-Durán
MFMaría Esther Durán Florez
María Esther Durán Florez
Luis Javier Ezquerra CalvoLuis Javier Ezquerra Calvo
Luis Javier Ezquerra Calvo
PCPablo Cardenal-Morales
Pablo Cardenal-Morales
MSMassimo Santella
Massimo Santella
Primary tracheal neoplasia is uncommon in domestic animals and humans, and most reported tracheal tumours are malignant. To the authors’ knowledge, this case represents the third confirmed case of tracheal leiomyoma reported in dogs. In human medicine, tracheal leiomyomas have also only been reported sporadically and account for approximately 1% of tracheal tumours. A 12-year-old spayed female Pit Bull was presented as an emergency because of an acute worsening of recurrent respiratory signs that were refractory to medical treatment. On initial evaluation, reduced mobility of both arytenoid cartilages was observed, and left arytenoid lateralisation was therefore performed. However, four days after the procedure, the dog continued to experience severe episodes of respiratory distress requiring orotracheal intubation. Subsequent bronchoscopy revealed an intraluminal tracheal mass occupying approximately 90% of the airway lumen. Because of this obstruction, an emergency temporary tracheostomy was performed caudal to the mass. Once the dog had been clinically stabilised, computed tomography was performed for surgical planning. Surgical treatment consisted of segmental tracheal resection and end-to-end anastomosis, with removal of a segment corresponding to 24% of the total tracheal length. Histopathological examination confirmed the diagnosis of tracheal leiomyoma. Complete surgical excision was achieved, supporting a favourable prognosis.

3 March 2026 in Veterinary Sciences
Verified
Journal Article
Open access
PDF file
PCPablo Cardenal-Morales
Pablo Cardenal-Morales
JCJosé Ignacio Cristóbal
José Ignacio Cristóbal
RCRafael Barrera Chacón
Rafael Barrera Chacón
AEAlberto Ezquerra-Durán
Alberto Ezquerra-Durán
PNPaloma Nicolas
Paloma Nicolas
Javier DuqueJavier Duque
Javier Duque
Myxomatous mitral valve disease (MMVD) is the most common acquired heart valve disease in dogs and it may contribute to cardiovascular–renal axis disorders (CvRD) in dogs. Sensitive and early biomarkers of renal involvement are needed. In this prospective and observational study, 84 dogs were enrolled (20 healthy dogs and 64 dogs with MMVD), categorised using the American College of Veterinary Internal Medicine guidelines. Serum and urinary parameters were analysed, including tubular biomarkers expressed as creatinine-ratios: urinary alkaline phosphatase (uALPc), gamma-glutamyl transferase (uGGTc), N-acetyl-β-D-glucosaminidase (uNAGc), and cystatin C (uCystc). uALPc, uGGTc, and uNAGc were higher in MMVD than in controls; uALPc and uGGTc were increased from stage B1, uNAGc was higher in stages with cardiomegaly (B2 and C+D), and uCystc increased mainly in clinical stages (C+D). Serum renal markers increased only in clinical stages. ROC analysis showed good discrimination for MMVD with uALPc (AUC 0.87) and uGGTc (0.86); for cardiomegaly with uALPc (0.77) and uNAGc (0.75); and for congestive heart failure with SDMA (0.85) and uCystc (0.75). No urinary biomarker was associated with daily furosemide dose. Urinary tubular biomarkers, particularly uALPc and uGGTc, detect early CvRD in dogs with MMVD and complement traditional serum markers.